Company Overview of LFB S.A.
Laboratoire Français du Fractionnement et des Biotechnologies Société Anonyme, a biopharmaceutical company, develops, manufactures, and markets medicinal products for the treatment of serious and rare diseases in the therapeutic areas of immunology, haemostasis, and intensive care worldwide. The company offers immunoglobulins, such as TEGELINE, which is used for multifocal motor neuropathy and chronic inflammatory demyelinating polyradiculoneuropathy; CLAIRYG, a ready-to-use liquid polyvalent human immunoglobulin; and hepatitis B immunoglobulin for hepatitis B immunoprophylaxis treatment. It also provides WILFACTIN, ALFALASTIN, FACTANE, and BETAFACT for rare diseases/haemostasis. The company...
3, avenue des Tropiques
Les Ulis, 91958
33 1 69 82 70 10
33 1 69 07 19 03
Key Executives for LFB S.A.
Chairman, Chief Executive Officer, Chairman of LFB Biotechnologies and Chief Executive Officer of LFB Biomedicaments
Executive Vice-President of Finance & Strategy
Chief Executive Officer of LFB Hemoderivados E Biotecnologia Ltda, Brazil
Sales Director and Executive Vice-President of Global Marketing & Sales - Lfb Biomedicaments Sa
Managing Director of Europlasma AT GmbH
Compensation as of Fiscal Year 2014.
LFB S.A. Key Developments
The LFB Group Announces Financial Results for the Financial Year Ended 31 December 2014
Apr 10 15
The LFB Group announced financial results for the financial year ended 31 December 2014. For the year, the company reported sales revenue of €501.9 million against €477.2 million a year ago. Net result was €13 million against €8.2 million a year ago. Net debt was down from €45.4 million at the end of 2013 to €41.3 million at the end of 2014. Due to elements and to the reversals of provisions allowed by a normalization of the commercial situation in Brazil, the group operating profit reached €25.2 million against €19.8 million in 2013.
LFB SA Begins First Patient Treatment with New Coagulation Factor VIIa (Recombinant) in Global Phase 3 Clinical Trial in Hemophilia A and B with Inhibitors
May 14 14
LFB SA, through its U.S. subsidiary, announced that the first patient has begun treatment with LR769 in a Phase 3 clinical trial of this novel recombinant form of human Factor VIIa in patients with congenital hemophilia A or B with inhibitors. This Phase 3 clinical trial is a global open-label, multicenter study designed to evaluate the efficacy, safety and pharmacokinetics of LR769 in adolescent and adult hemophilia A and B patients with inhibitors. The study will evaluate two dosing regimens for the treatment of bleeding episodes and should be completed in 2015. The start of patient treatment is an important milestone in the development of LR769 for hemophilia A and B patients with inhibitors to Factor VIII or IX. Based on promising data from earlier studies, the company believes that LR769 has the potential to be a significant advance for people with hemophilia, and it will fully explore its potential as the first new therapeutic option in more than 15 years. Additional Phase 3 studies will assess the efficacy of LR769 for the treatment of bleeding episodes in pediatric hemophilia patients with inhibitors and will evaluate the prevention of bleeding complications in patients undergoing surgery. These studies are expected to start in early 2015.
LFB SA Initiates Global Phase 3 Clinical Trial of New Coagulation Factor VIIa (Recombinant) in Patients with Hemophilia A and B
Mar 3 14
LFB SA announced initiation of the global Phase 3 program for LR769, a novel recombinant form of human Factor VIIa, in patients with congenital hemophilia A or B with inhibitors. LR769 was developed using rPRO(TM) technology and is being developed for treatment and prevention of bleeding episodes in hemophilia A and B patients with inhibitors to Factor VIII or IX. The initial Phase 3 clinical trial is an open-label, multicenter study designed to evaluate the efficacy, safety and pharmacokinetics of LR769 in adolescent and adult hemophilia A and B patients with inhibitors. The study will evaluate two dosing regimens for the treatment of bleeding episodes. Initial results, expected in the second half of 2013, will provide the basis for subsequent studies. The second study will assess the efficacy of LR769 for the treatment of bleeding episodes in pediatric hemophilia patients with inhibitors. The third study will evaluate the prevention of bleeding complications in patients undergoing surgery. Both are expected to start early 2015.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|